Treating Blood Cancers

Marybeth Medicke, MSN, RN, El Paso Community College, El Paso, TX Recorded on November 21, 2019 What is compassion fatigue? How does it differ from burnout? What behaviors do healthcare professionals with compassion fatigue exhibit? What can you do to stay engaged in your work? In this episode, Marybeth Medicke, MSN, RN, a registered nurse and faculty member at the El Paso Community College discusses the challenges of caring for a patient with cancer and shares her journey of leaving, and eventually returning to, the field of oncology. Marybeth Medicke, MSN, RN Registered Nurse and Faculty Member El Paso Community CollegeEl Paso, TX

Anita Kumar, MD, Memorial Sloan Kettering Cancer Center, Basking Ridge, NJ Recorded on November 11, 2019 What is mantle cell lymphoma (MCL)? How is it diagnosed? How does it differ from chronic lymphocytic leukemia? In this episode, Dr. Anita Kumar of Memorial Sloan Kettering Cancer Center breaks down the biology of the disease, addresses new and emerging treatment options, and discusses approaches to both indolent and aggressive MCL. Tune in for a comprehensive understanding of MCL today! Anita Kumar, MD Medical Oncologist Memorial Sloan Kettering Cancer CenterBasking Ridge, NJ

Susan McCall, MSN, ANP-BC, AOCNP®, Memorial Sloan Kettering Cancer Center, New York, NY Recorded on September 18, 2019 How do healthcare professionals communicate with patients about the issues related to living with a chronic disease? In this episode, Susan McCall, ANP-BC, AOCNP®, a nurse practitioner at Memorial Sloan Kettering Cancer Center in New York, discusses her role in educating patients and their caregivers on living with non-Hodgkin lymphoma, treatment, including clinical trials, financial and fertility concerns, psychosocial considerations, and more. Tune in today! Susan J. McCall, MSN, ANP-BC, AOCNP® Clinical Trials Nurse Practitioner Lymphoma Service Memorial Sloan Kettering Cancer Center New York, NY

Elizabeth A. Weber, BSN, RN, Heather DiFilippo, MSN, CRNP and Erin Medoff, RN, MSN, APRN Recorded live at The Leukemia & Lymphoma Society’s Symposium on CAR T-cell Therapy on June 28, 2019 In this episode, we are joined by three nurses to discuss their important and varied roles in treating patients with CAR T-cell therapy: Elizabeth Weber, who serves as a logistical nurse navigator, and Heather DiFilippo and Erin Medoff, both advanced practice nurses. Our guests discuss the importance of the continuity of care nurses provide, their role in educating patients and families about CAR T therapy, how to navigate this process, and much more. Tune in today! Elizabeth A. Weber, BSN, RNCommercial Cellular Therapy CoordinatorUniversity of Pennsylvania Health SystemPhiladelphia, PA Heather DiFilippo, MSN, CRNPCertified Adult Nurse PractitionerUniversity of Pennsylvania Health SystemPhiladelphia, PA Erin Medoff, RN, MSN, APRNOncology Nurse PractitionerMalignant HematologyYale New Haven HospitalNew Haven, CTAssistant Clinical ProfessorYale University School of NursingOrange, CT

Frederick L. Locke, MD, Moffitt Cancer Center, Tampa, FL Recorded on September 3, 2019 Join Dr. Miller as he speaks with Dr. Frederick Locke from Moffitt Cancer Center in Tampa, FL on the future of CAR T-cell therapy. In this episode, Dr. Locke discusses new indications for treatment, including off-the-shelf CAR T-cells, earlier lines of therapy, allogeneic treatment options, the necessity for preparative regimens, suicide genes, dual antigen binding, and so much more. Listen in today! Frederick L. Locke, MD Vice-Chair Research Director and Medical Director, Immune Cell Therapy Program Department of Blood and Marrow Transplant and Cellular Immunotherapy Co-Leader Immunology Program Moffitt Cancer Center Tampa, FL This podcast episode is supported by Allogene Therapeutics, Inc.

Sergio Giralt, MD, Memorial Sloan Kettering Cancer Center and Gunjan Shah, MD, Memorial Sloan Kettering Cancer Center Recorded live at The Leukemia & Lymphoma Society’s Symposium on CAR T-cell Therapy on June 28, 2019 Tune in as Dr. Sergio Giralt and Dr. Gunjan Shah, hematologist-oncologists at Memorial Sloan Kettering Cancer Center in New York, discuss adverse effects and financial toxicities associated with chimeric antigen receptor (CAR) T-cell therapy. In this episode, Dr. Giralt discusses how cytokine release syndrome (CRS), neurotoxicities, and other side effects affect patients receiving CART therapy, and Dr. Shah reviews the challenges associated with the high cost of treatment and care. Sergio Giralt, MD Chief Attending Adult Bone Marrow Transplant Service Memorial Sloan Kettering Cancer Center New York, NY Gunjan Shah, MD Adult Bone Marrow Transplant Servicefor Health Policy & OutcomesMemorial Sloan Kettering Cancer Center New York, NY

Dennis Cooper, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ Recorded live at The Leukemia & Lymphoma Society’s Symposium on CAR T-cell Therapy on June 28, 2019 What is CAR T-cell therapy? Listen in as Dr. Dennis Cooper, Professor of Medicine and Chief of the Bone Marrow Transplant Service at Rutgers Cancer Institute of New Jersey, reviews the principles of CAR T-cell therapy, discusses the treatment process and efficacy, and highlights future advances. Dennis Cooper, MD Chief, Blood and Marrow Transplantation Medical Oncologist Rutgers Cancer Institute of New Jersey New Brunswick, NJ

Susan O’Brien, MD, University of California, Irvine, CA Recorded on April 5, 2019 In this episode, Dr. Ken Miller speaks with Dr. Susan O’Brien, a hematologist/oncologist at the University of California, Irvine about the standard of care for patients with chronic lymphocytic leukemia. Dr. O’Brien describes the biology of CLL, the complexities of available treatment options, how to choose a drug sequence, the clinical and laboratory workup, the issues surrounding watch and wait, and long-term and late effects. Susan O’Brien, MD Associate Director for Clinical Science Chao Family Comprehensive Cancer Center Medical Director Sue and Ralph Stern Center for Cancer Clinical Trials & Research Professor of Medicine, Division of Hematology/Oncology Department of Medicine, University of California, Irvine Irvine, CA

Amy Burd, PhD, Vice President of Research and Strategy, and Alissa Gentile, MSN, RN, Director of the Clinical Trial Support Center at The Leukemia & Lymphoma Society Recorded on May 10, 2019 Join Dr. Ken Miller as he speaks with Dr. Amy Burd, Vice President of Research and Strategy, and Alissa Gentile, Director of the Clinical Trial Support Center at The Leukemia & Lymphoma Society about LLS’ role in advancing treatment therapies for acute myeloid leukemia (AML). Their discussion focuses on the Beat AML® Master Trial, an innovative clinical trial which matches therapies to patients based on their individual genetic profile, and the role LLS plays in supporting and connecting patients to clinical trials. Amy Burd, PhD Alissa Gentile, MSN, RN

Brad Zebrack, PhD, MSW, The University of Michigan School of Social Work, Ann Arbor, MI Recorded on March 5, 2019 Dr. Brad Zebrack, Professor of Social Work at The University of Michigan School of Social Work in Ann Arbor, MI, shares his insights into the unique challenges faced by young adult cancer survivors. Dr. Zebrack discusses young adult survivors’ struggle for independence, challenges with body image and intimacy, issues navigating financial and career challenges, young adult survivors’ desire to feel “normal” amongst their peers, and how the healthcare team can help. Brad Zebrack, PhD, MSW Professor of Social Work The University of Michigan School of Social Work Ann Arbor, MI

Richard, MDS survivor since 2016, Nancy, Caregiver, and Vu Duong, MD, University of Maryland School of Medicine, Baltimore, MD Recorded on February 26, 2019 In this episode, Dr. Miller speaks with Richard, an MDS survivor, his wife Nancy and treating physician, Dr. Vu Duong, an Assistant Professor of Medicine at the University of Maryland School of Medicine in Baltimore, MD as they discuss their unique perspectives on the patient’s treatment for MDS and the outcomes. Richard, MDS survior since 2016 Nancy, Caregiver Vu Duong, MD Assistant Professor of MedicineUniversity of Maryland School of MedicineBaltimore, MD

Raymond Comenzo, MD, Tufts Medical Center, Boston, MA Recorded on December 14, 2018 In this episode, Dr. Raymond Comenzo, a hematologist/oncologist at Tufts University School of Medicine in Boston, MA, breaks down the biology of AL amyloidosis, how it affects organs throughout the body, and how it is being treated in the hospital today. AL amyloidosis is a rare disorder in which there is a buildup of an abnormal protein called amyloid. Amyloid is typically produced in the bone marrow, but can be deposited in any tissue or organ causing the organ not to function properly. It is often hard to diagnose because the signs and symptoms can be the same as those of more common diseases and it is important to diagnosis as early as possible so that further organ damage is prevented. Raymond Comenzo, MD John C. Davis Myeloma and Amyloid Program Tufts Medical Center Professor of Medicine Tufts University School of Medicine Boston, MA

Lewis Silverman, MD, Boston Children’s Hospital, Boston, MA Recorded on February 7, 2019 Learn more as Dr. Lewis Silverman, a pediatric hematologist-oncologist at Boston Children’s Hospital in Boston, MA, discusses medical advances in pediatric hematologic malignancies, the role of immunotherapy, late relapse, the role of checkpoint inhibitors, and improving the quality of cure with a focus on acute lymphoblastic leukemia. Lewis Silverman, MD Pediatric Hematologist-Oncologist Boston Children’s Hospital Boston, MA

Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA Recorded on December 28, 2018 The conversation continues with Dr. Richardson in Part II of a two part episode on myeloma by describing the phases of treatment: induction remission therapy, consolidation and maintenance. Dr. Richardson provides an in-depth view of real-world issues patients experience, describes combination drug therapies and new treatments, addresses the clinical benefit of transplant for individual patients and the difference between tandem and autotransplant, and the important role of the multidisciplinary healthcare team.Paul Richardson, MD Clinical Program Leader Director of Clinical Research Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Boston, MA

Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA Recorded on December 28, 2018 On Part I of a two part episode, Dr. Ken Miller talks with Dr. Paul Richardson, a hematologist/oncologist at Dana-Farber Cancer Center in Boston, MA, as he describes his journey as a clinical investigator and how that journey shaped his perspective when treating patients. Dr. Richardson discusses the biology of the disease, state-of-the-art care, how smoldering myeloma differs from the disease of myeloma, the use of vaccines in cancer treatment, and so much more!Paul Richardson, MD Clinical Program Leader Director of Clinical Research Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Boston, MA

Alice Mims, MD, MSCR, The James, The Ohio State University Comprehensive Cancer Center, Columbus, OH Recorded on January 10, 2019 For many decades, treatment for AML remained stagnant. In recent years, new options have emerged. Join Dr. Ken Miller as he questions Dr. Alice Mims of The Ohio State University Comprehensive Cancer Center in Columbus, Ohio about these treatment updates. Dr. Mims also discusses how to tailor treatment to the patient’s goals of care, common mutations found in AML, and reviews the Beat AML® Master Trial.Alice Mims, MD, MSCR Medical Oncologist The James, The Ohio State University Comprehensive Cancer Center Columbus, OH

Naveen Pemmaraju, MD, MD Anderson Cancer Center, Houston, TX Recorded on December 11, 2018 Join Drs. Naveen Pemmaraju and Ken Miller as they discuss the diagnosis, treatment, and management of blastic plasmacytoid dendritic cell neoplasm (BPDCN), an often misdiagnosed and highly aggressive hematologic malignancy. Dr. Pemmaraju is a hematologist/oncologist at MD Anderson Cancer Center in Houston, TX. On this episode, Dr. Pemmaraju discusses the origin of BPDCN, methods of diagnosing and treating this rare disease, and the progress being made in the field. BPDCN Drug Updates: On December 21, 2018, the U.S. Food and Drug Administration (FDA) approved ELZONRIS (tagraxofusp) — the first treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients two years and older. For additional drug information, please visit: www.LLS.org/Drugs. Naveen Pemmaraju, MD Associate Professor Department of Leukemia MD Anderson Cancer Center Houston, TX